Jazz Pharmaceuticals JAZZ Payments to Acquire Intangible Assets
Payments to Acquire Intangible Assets at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireIntangibleAssets.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's payments to acquire intangible assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's payments to acquire intangible assets?
- Jazz Pharmaceuticals (JAZZ) reported payments to acquire intangible assets of $0 in Q1 2026.
- How has Jazz Pharmaceuticals's payments to acquire intangible assets changed year-over-year?
- Jazz Pharmaceuticals's payments to acquire intangible assets decreased by 100.0% year-over-year, from $25M to $0.
- What is the long-term trend for Jazz Pharmaceuticals's payments to acquire intangible assets?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's payments to acquire intangible assets has grown at a 56.9% compound annual growth rate (CAGR), from $17.89M to $108.5M.
- What does payments to acquire intangible assets mean?
- Cash spent on acquiring non-physical assets like patents or licenses.
- How do you interpret payments to acquire intangible assets?
- Higher spending indicates a strong focus on R&D pipeline expansion or securing competitive advantages through intellectual property.
- How does payments to acquire intangible assets compare across companies?
- Highly relevant for technology and pharmaceutical sectors where IP is a primary value driver.